Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder

Bipolar Disorders

Volumn 10, Issue 2, 2008, Pages 342-348

  Van Winkel, Ruud ^a   De Hert, Marc ^a   Van Eyck, Dominique ^a   Hanssens, Linda ^b   Wampers, Martien ^a   Scheen, Andre ^c   Peuskens, Joseph ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bipolar disorder; Diabetes; Metabolic syndrome; Physical health

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; GLUCOSE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; RATING SCALE;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIABETES MELLITUS; DRUG THERAPY; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; SCHIZOPHRENIA;

EID: 43149091185     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2007.00520.x     Document Type: Article

References (44)

1. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: A systematic review. Schizophr Res 2004; 71: 195-212.
2. Allison DB, Casey DE. Antipsychotic-induced weight gain: A review of the literature. J Clin Psychiatry 2001; 62 (Suppl. 7): 22-31.
3. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1-17.
4. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 published cases. Ann Clin Psychiatry 2002; 14: 59-64.
5. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001;62 (Suppl. 27): 15-26; discussion 40-41.
6. Scheen AJ, De Hert M. Drug-induced diabetes mellitus: The example of atypical antipsychotics. Rev Med Liege 2005; 60: 455-60.
7. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005; 19 (Suppl. 1): 1-93.
8. De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J. Conference report: Belgian consensus on metabolic problems associated with second-generation antipsychotics. Int J Psychiat Clin 2005; 9: 130-137.
9. De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: Fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006; 21 (Suppl. 2): S11-S15.
10. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64: 575-579.
11. Basu R, Brar JS, Chengappa KN et. al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 2004; 6: 314-318.
12. De Hert M, van Winkel R, Van Eyck D et. al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006; 83: 87-93.
13. Lilliker SL. Prevalence of diabetes in a manic-depressive population. Compr Psychiatry 1980; 21: 270-275.
14. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999; 156: 1417-1420.
15. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70: 19-26.
16. Taylor D, Young C, Mohamed R, Paton C, Walwyn R. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 2005; 19: 182-186.
17. Sernyak MJ, Gulanski B, Rosenheck R. Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. J Clin Psychiatry 2005; 66: 1463-1467.
18. van Winkel R, De Hert M, Van Eyck D et. al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: Evaluation of incidence and screening methods. J Clin Psychiatry 2006; 10: 1493-1500.
19. De Hert M, Van Eyck D, Hanssens L et. al. Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? Eur Psychiatry 2006; 21: 224-226.
20. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: Findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7: 424-430.
21. Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000; 61: 179-184.
22. McElroy SL, Frye MA, Suppes T et. al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63: 207-213.
23. Fagiolini A, Frank E, Houck PR et. al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002; 63: 528-533.
24. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003; 160: 112-117.
25. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001; 62: 486-491; quiz 492-493.
26. De Hert M, Peuskens B, van Winkel R et al. Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE(R). Schizophr Res 2006; 88: 222-226.
27. De Hert M, Hanssens L, van Winkel R et. al. A case series: Evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007; 33: 823-830.
28. De Hert M, Hanssens L, van Winkel R et al. Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. Diabetes Care 2006; 29: 2329-2330.
29. Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
30. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
31. International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels: IDF, 2005.
32. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29: S43-S48.
33. Rietzschel E, De Buyzere M, De Bacquer D et. al. Metabolic syndrome, a map of the cardiovascular damage. Results from the asklepios study in 2528 apparently healthy 35-55 year old subjects. Abstracts from the Conference of the European Society of Cardiology. Eur Heart J 2005; 26: 110-111.
34. Walckiers D, Van der Veken J, Papoz L, Stroobant A. Prevalence of drug-treated diabetes mellitus in Belgium. Results of a study with the collaboration of a network of pharmacies. Eur J Clin Pharmacol 1992; 43: 613-619.
35. Marder SR, Essock SM, Miller AL et. al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-1349.
36. Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr 2006; 11: 32-39.
37. Ferreira I, Twisk JW, van Mechelen W, Kemper HC, Stehouwer CD. Development of fatness, fitness, and lifestyle from adolescence to the age of 36 years: Determinants of the metabolic syndrome in young adults: the Amsterdam growth and health longitudinal study. Arch Intern Med 2005; 165: 42-48.
38. Boulogne A, Vantyghem M. Epidemiological data and screening criteria of the metabolic syndrome. Presse Med 2004; 5: 662-665.
39. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-1076.
40. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444-2449.
41. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
42. De Hert M, van Winkel R, Van Eyck D et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: A cross-sectional study. Clin Pract Epidemol Ment Health 2006; 2: 14.
43. McEvoy JP, Meyer JM, Goff DC et. al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32.
44. Ford ES, Mokdad AH, Giles WH, Galuska DA, Serdula MK. Geographic variation in the prevalence of obesity, diabetes, and obesity-related behaviors. Obes Res 2005; 13: 118-122.